A recent study explored the response to treatment for amblyopia with the Luminopia device after at least 12 weeks of use.

While patching the fellow eye is the typical treatment for amblyopia, Luminopia is a virtual reality therapy where patients watch “age-appropriate television content modified with contrast reduction and dichoptic masking,” notes the abstract from the presentation at ARVO 2024.

The multicenter observational registry enrolled 62 patients with amblyopia and a history of prior treatments, including patching. The average age of the patients was 8 years old. Data on visual function and treatment adherence were collected retrospectively. “The primary outcome was change in interocular difference (IOD) in best-corrected visual acuity (BCVA) at follow-up.”

IOD in BCVA improved by 0.7 lines at first follow-up (84±39 days post-prescription), and at the most recent follow-up (131±55 days post prescription), 28 patients (47%) showed an improvement of ≥1 line in amblyopic eye BCVA. Median treatment adherence was 70%, and no safety events were reported.

The presentation abstract concluded: “IOD and amblyopia eye BCVA improvements were clinically meaningful, especially considering older age and high proportion with prior treatment.” The data supported a 2022 clinical trial.

A full list of author disclosures can be found in the published research